CTI Biopharma Corp reports results for the quarter ended in June - Earnings Summary

CTI Biopharma

06/08/2021 15:39

* CTI Biopharma Corp  CTIC.OQ  reported a quarterly adjusted
loss of 21 cents​​ per share for the quarter ended in June. The
mean expectation of five analysts for the quarter was for a loss
of 21 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* CTI Biopharma Corp's reported EPS for the quarter was a loss
of 21 cents​.
* The mean earnings estimate of analysts had risen by about 4.5%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* CTI Biopharma Corp shares had risen by 1.2% this quarter and
lost 21.4% so far this year.
* The company reported a quarterly loss of $19.68 million.
* Wall Street's median 12-month price target for CTI Biopharma
Corp is $6.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 6 at 02:39 p.m.  ​All
figures in US dollars unless otherwise stated